 Connection
Prem Subramanian to Exophthalmos
This is a "connection" page, showing publications Prem Subramanian has written about Exophthalmos.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.076 |
|
|
|
-
Subramanian PS, Cho RI, Kahana A. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr Opin Ophthalmol. 2023 Nov 01; 34(6):487-492.
Score: 0.863
-
Hoang TT, Tran HMD, Van Truong B, Subramanian P. Presentation of High-Flow Cerebral Proliferative Angiopathy With Adie's-Like Pupil and Proptosis. J Neuroophthalmol. 2021 Jun 01; 41(2):e184-e185.
Score: 0.739
-
Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, Tang R, Nguyen QT, Maamari RN, Ugradar S, Hsu K, Karon M, Stan MN. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. J Clin Endocrinol Metab. 2023 12 21; 109(1):25-35.
Score: 0.221
-
Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison. JAMA Ophthalmol. 2022 04 01; 140(4):328-335.
Score: 0.196
-
Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. Thyroid. 2024 Jul; 34(7):880-889.
Score: 0.057
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|